SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 4.9% Stake in Sage Therapeutics

RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a beneficial ownership of 4.9% of Sage Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Sage Therapeutics, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 3,002,370 shares of Sage Therapeutics, Inc. Common Stock.
• This ownership represents 4.9% of the outstanding Common Stock, calculated based on 61,173,263 shares outstanding as of October 22, 2024, as reported in the Company's Form 10-Q.
• RTW Investments, LP, a Delaware limited partnership, acts as an investment adviser to certain funds (the "RTW Funds") which directly hold these shares.
• Dr. Roderick Wong, a U.S. citizen, is the Managing Partner and Chief Investment Officer of RTW Investments.
• The shares are held in the ordinary course of business and were not acquired for the purpose of changing or influencing the control of Sage Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G/A) disclosing beneficial ownership. It is neutral in sentiment as it simply reports factual ownership data without expressing positive or negative views on the company's performance or prospects.

Future Outlook

This document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

Schedule 13G filings are standard disclosures in the investment industry, indicating that an institutional investor or group has acquired beneficial ownership of more than 5% (or in this case, just under 5% for a 13G/A amendment) of a company's voting class of securities, held in the ordinary course of business without intent to control or influence the issuer. This filing provides transparency regarding significant passive investment stakes in publicly traded companies like Sage Therapeutics, which operates in the biotechnology sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive ownership stake by an investment firm, which can offer insights into institutional interest in the company's stock.

Key Dates

Keywords

Sage Therapeutics, RTW Investments, Roderick Wong, SEC filing, Schedule 13G, beneficial ownership, common stock, investment adviser, biotechnology, pharmaceuticals